iBio (NYSE:IBIO) Research Coverage Started at Brookline Capital Management

Research analysts at Brookline Capital Management assumed coverage on shares of iBio (NYSE:IBIO) in a research report issued to clients and investors on Monday, Benzinga reports. The firm set a “buy” rating and a $3.60 price target on the stock. Brookline Capital Management’s price target indicates a potential upside of 63.64% from the company’s current price.

Several other equities analysts also recently issued reports on IBIO. StockNews.com initiated coverage on iBio in a research report on Saturday, April 20th. They issued a “sell” rating for the company. Chardan Capital restated a “buy” rating and set a $5.00 target price on shares of iBio in a research report on Monday, June 3rd.

iBio Price Performance

Shares of IBIO stock traded up $0.05 during mid-day trading on Monday, reaching $2.20. The stock had a trading volume of 22,780 shares, compared to its average volume of 1,813,491. The company has a 50 day moving average of $2.19. The company has a current ratio of 1.69, a quick ratio of 1.69 and a debt-to-equity ratio of 0.04. iBio has a one year low of $1.02 and a one year high of $15.99.

iBio (NYSE:IBIO) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.71) EPS for the quarter. As a group, equities analysts expect that iBio will post -99.82 EPS for the current year.

Institutional Investors Weigh In On iBio

A number of institutional investors have recently made changes to their positions in the stock. Lynx1 Capital Management LP acquired a new position in iBio in the first quarter valued at about $2,436,000. Ikarian Capital LLC acquired a new position in iBio in the first quarter valued at about $2,436,000. Finally, Opaleye Management Inc. acquired a new position in iBio in the first quarter valued at about $2,761,000. 7.90% of the stock is owned by institutional investors and hedge funds.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.